Baloxavir (BioDeep_00000839684)
代谢物信息卡片
Baloxavir
化学式: C24H19F2N3O4S (483.10642780000006)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COCC2N1C(=O)C3=C(C(=O)C=CN3N2C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F)O
InChI: InChI=1S/C24H19F2N3O4S/c25-16-6-5-13-15(20(16)26)12-34-18-4-2-1-3-14(18)21(13)29-19-11-33-10-9-27(19)24(32)22-23(31)17(30)7-8-28(22)29/h1-8,19,21,31H,9-12H2/t19-,21+/m1/s1
描述信息
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11278
- KEGGdrug: D97646
- PubChem: 124081876
- ChEMBL: CHEMBL4297215
- CAS: 1985605-59-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Irina Gaisina, Ping Li, Ruikun Du, Qinghua Cui, Meiyue Dong, Chengcheng Zhang, Balaji Manicassamy, Michael Caffrey, Terry Moore, Laura Cooper, Lijun Rong. An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil.
Science advances.
2024 Feb; 10(8):eadk9004. doi:
10.1126/sciadv.adk9004. [PMID: 38394202] - Yanmei Liu, Sylvie Retout, Vincent Duval, Jingying Jia, Yang Zou, Yijun Wang, Valérie Cosson, Sébastien Jolivet, Stefan De Buck. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals.
Clinical and translational science.
2022 05; 15(5):1196-1203. doi:
10.1111/cts.13237. [PMID: 35176206] - Yun Kim, Sangwon Lee, Yohan Kim, In-Jin Jang, SeungHwan Lee. Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects.
Clinical and translational science.
2022 02; 15(2):422-432. doi:
10.1111/cts.13160. [PMID: 34664769] - Lin Tang, Haiyan Yan, Weibin Wu, Dawei Chen, Zhenxiong Gao, Jinqiang Hou, Cunlong Zhang, Yuyang Jiang. Synthesis and Anti-Influenza Virus Effects of Novel Substituted Polycyclic Pyridone Derivatives Modified from Baloxavir.
Journal of medicinal chemistry.
2021 10; 64(19):14465-14476. doi:
10.1021/acs.jmedchem.1c00979. [PMID: 34549580] - Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2021 Oct; 54(5):767-775. doi:
10.1016/j.jmii.2021.05.011. [PMID: 34253490] - Zeineb Mhamdi, Julie Carbonneau, Marie-Christine Venable, Mariana Baz, Yacine Abed, Guy Boivin. Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
The Journal of general virology.
2021 10; 102(10):. doi:
10.1099/jgv.0.001659. [PMID: 34661516] - Andrei A Ivashchenko, Oleg D Mitkin, Jeremy C Jones, Alexander V Nikitin, Angela G Koryakova, Ruben N Karapetian, Dmitry V Kravchenko, Stephan V Mochalov, Alexey A Ryakhovskiy, Vladimir Aladinskiy, Irina A Leneva, Irina N Falynskova, Ekaterina A Glubokova, Elena A Govorkova, Alexandre V Ivachtchenko. Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.
The Journal of antimicrobial chemotherapy.
2021 03; 76(4):1010-1018. doi:
10.1093/jac/dkaa524. [PMID: 33367751] - Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Feb; 157(?):105631. doi:
10.1016/j.ejps.2020.105631. [PMID: 33115675] - Yoshinori Ando, Takeshi Noshi, Kenji Sato, Toru Ishibashi, Yuki Yoshida, Takahiro Hasegawa, Motoyasu Onishi, Mitsutaka Kitano, Ryoko Oka, Makoto Kawai, Ryu Yoshida, Akihiko Sato, Takao Shishido, Akira Naito. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
The Journal of antimicrobial chemotherapy.
2021 01; 76(1):189-198. doi:
10.1093/jac/dkaa393. [PMID: 33035324] - Lei Zhao, Jinjing Che, Qian Zhang, Yiming Li, Xiaojia Guo, Lixia Chen, Hua Li, Ruiyuan Cao, Xingzhou Li. Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach.
Molecules (Basel, Switzerland).
2020 Nov; 25(22):. doi:
10.3390/molecules25225291. [PMID: 33202790] - Mitsutaka Kitano, Takanobu Matsuzaki, Ryoko Oka, Kaoru Baba, Takahiro Noda, Yuki Yoshida, Kenji Sato, Kohei Kiyota, Tohru Mizutare, Ryu Yoshida, Akihiko Sato, Hiroshi Kamimori, Takao Shishido, Akira Naito. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Influenza and other respiratory viruses.
2020 11; 14(6):710-719. doi:
10.1111/irv.12760. [PMID: 32533654] - Liva Checkmahomed, Blandine Padey, Andrés Pizzorno, Olivier Terrier, Manuel Rosa-Calatrava, Yacine Abed, Mariana Baz, Guy Boivin. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Viruses.
2020 10; 12(10):. doi:
10.3390/v12101139. [PMID: 33049959] - Mira C Patel, Vasiliy P Mishin, Juan A De La Cruz, Anton Chesnokov, Ha T Nguyen, Malania M Wilson, John Barnes, Rebecca J G Kondor, David E Wentworth, Larisa V Gubareva. Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
Antiviral research.
2020 10; 182(?):104906. doi:
10.1016/j.antiviral.2020.104906. [PMID: 32798601] - Takato Yokoyama, Hiroki Sakaguchi, Toru Ishibashi, Takao Shishido, Pedro A Piedra, Chisako Sato, Kenji Tsuchiya, Takeki Uehara. Baloxavir Marboxil 2\% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
The Pediatric infectious disease journal.
2020 08; 39(8):706-712. doi:
10.1097/inf.0000000000002748. [PMID: 32433222] - Emi Takashita, Takashi Abe, Hiroko Morita, Shiho Nagata, Seiichiro Fujisaki, Hideka Miura, Masayuki Shirakura, Noriko Kishida, Kazuya Nakamura, Tomoko Kuwahara, Keiko Mitamura, Masataka Ichikawa, Masahiko Yamazaki, Shinji Watanabe, Hideki Hasegawa. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Antiviral research.
2020 08; 180(?):104828. doi:
10.1016/j.antiviral.2020.104828. [PMID: 32574689] - Yacine Abed, Clément Fage, Liva Checkmahomed, Marie-Christine Venable, Guy Boivin. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Antiviral research.
2020 07; 179(?):104807. doi:
10.1016/j.antiviral.2020.104807. [PMID: 32343991] - Hiroki Koshimichi, Sylvie Retout, Valerie Cosson, Vincent Duval, Stefan De Buck, Yoshiyuki Tsuda, Toru Ishibashi, Toshihiro Wajima. Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications.
Antimicrobial agents and chemotherapy.
2020 06; 64(7):. doi:
10.1128/aac.00119-20. [PMID: 32312784] - Zhanwei Du, Ciara Nugent, Alison P Galvani, Robert M Krug, Lauren Ancel Meyers. Modeling mitigation of influenza epidemics by baloxavir.
Nature communications.
2020 06; 11(1):2750. doi:
10.1038/s41467-020-16585-y. [PMID: 32487990] - Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou. Advance of promising targets and agents against COVID-19 in China.
Drug discovery today.
2020 05; 25(5):810-812. doi:
10.1016/j.drudis.2020.02.011. [PMID: 32198066] - Anton Chesnokov, Mira C Patel, Vasiliy P Mishin, Juan A De La Cruz, Lori Lollis, Ha T Nguyen, Vivien Dugan, David E Wentworth, Larisa V Gubareva. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
The Journal of infectious diseases.
2020 01; 221(3):367-371. doi:
10.1093/infdis/jiz472. [PMID: 31541547] - Bo Li, Sara M Clohisey, Bing Shao Chia, Bo Wang, Ang Cui, Thomas Eisenhaure, Lawrence D Schweitzer, Paul Hoover, Nicholas J Parkinson, Aharon Nachshon, Nikki Smith, Tim Regan, David Farr, Michael U Gutmann, Syed Irfan Bukhari, Andrew Law, Maya Sangesland, Irit Gat-Viks, Paul Digard, Shobha Vasudevan, Daniel Lingwood, David H Dockrell, John G Doench, J Kenneth Baillie, Nir Hacohen. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection.
Nature communications.
2020 01; 11(1):164. doi:
10.1038/s41467-019-13965-x. [PMID: 31919360] - Liva Checkmahomed, Zeineb M'hamdi, Julie Carbonneau, Marie-Christine Venable, Mariana Baz, Yacine Abed, Guy Boivin. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
The Journal of infectious diseases.
2020 01; 221(1):63-70. doi:
10.1093/infdis/jiz418. [PMID: 31419295] - Cy V Credille, Christine N Morrison, Ryjul W Stokes, Benjamin L Dick, Yifan Feng, Jiaxing Sun, Yao Chen, Seth M Cohen. SAR Exploration of Tight-Binding Inhibitors of Influenza Virus PA Endonuclease.
Journal of medicinal chemistry.
2019 11; 62(21):9438-9449. doi:
10.1021/acs.jmedchem.9b00747. [PMID: 31536340] - Vasiliy P Mishin, Mira C Patel, Anton Chesnokov, Juan De La Cruz, Ha T Nguyen, Lori Lollis, Erin Hodges, Yunho Jang, John Barnes, Timothy Uyeki, Charles T Davis, David E Wentworth, Larisa V Gubareva. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.
Emerging infectious diseases.
2019 10; 25(10):1969-1972. doi:
10.3201/eid2510.190607. [PMID: 31287050] - Hiroki Koshimichi, Toru Ishibashi, Toshihiro Wajima. Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients.
Journal of pharmaceutical sciences.
2019 09; 108(9):3112-3117. doi:
10.1016/j.xphs.2019.04.010. [PMID: 30998942] - Hiroki Koshimichi, Yoshiyuki Tsuda, Toru Ishibashi, Toshihiro Wajima. Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
Journal of pharmaceutical sciences.
2019 05; 108(5):1896-1904. doi:
10.1016/j.xphs.2018.12.005. [PMID: 30557562] - Hiroki Koshimichi, Toru Ishibashi, Nao Kawaguchi, Chisako Sato, Akira Kawasaki, Toshihiro Wajima. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
Clinical drug investigation.
2018 Dec; 38(12):1189-1196. doi:
10.1007/s40261-018-0710-9. [PMID: 30288682] - Shinya Omoto, Valentina Speranzini, Takashi Hashimoto, Takeshi Noshi, Hiroto Yamaguchi, Makoto Kawai, Keiko Kawaguchi, Takeki Uehara, Takao Shishido, Akira Naito, Stephen Cusack. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Scientific reports.
2018 06; 8(1):9633. doi:
10.1038/s41598-018-27890-4. [PMID: 29941893]